Please ensure Javascript is enabled for purposes of website accessibility

Why Omeros Stock Jumped Today

By Keith Speights – Updated Apr 19, 2019 at 11:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small biotech received good news from the FDA.

What happened

Shares of Omeros (OMER 8.08%) were 8.7% higher as of 3:21 p.m. EST on Thursday after rising as much as 12.7% earlier in the day. The biotech announced that it had reached an agreement with the U.S. Food and Drug Administration (FDA) that streamlines its path to filing for approval of experimental drug OMS721 in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) -- a complication resulting from stem cell transplants. 

So what

Any time the FDA makes it easier for a biotech to submit a new drug for approval, it's good news for the biotech. That's definitely the case for Omeros.

Hand holding beaker with dropper and other lab glassware in view

Image source: Getty Images.

Probably the most important news from the agreement with the FDA is that Omeros will be able to use data from its current phase 3 clinical study of OMS721 in HSCT-TMA without having to use historical control data. This means less work for Omeros and a speedier route to filing the Biologics License Application (BLA) for OMS721.

Omeros chairman and CEO Greg Demopulos hit the nail on the head with his remarks about the FDA agreement. Demopulos said, "We now have an even clearer and more streamlined path to submitting our BLA, saving time and crucial resources as we advance toward regulatory review and approval."

The FDA now says that it won't just consider accelerated approval for OMS721 in HSCT-TMA; the agency will also consider full regular approval of the drug. An accelerated approval requires a confirmatory post-approval clinical study, so a full approval that didn't require this step would definitely be great for Omeros.

Check out the latest Omeros earnings call transcript.

Now what

Omeros now plans to meet with European regulators to discuss aligning its submission for OMS721 with its FDA filing. The biotech will likely soon begin filing its rolling BLA submission for the drug in the U.S., beginning with the nonclinical section of the application that was completed in late 2018.

There's no guarantee that OMS721 will be approved. However, with no approved treatment for HSCT-TMA and promising clinical data so far, Omeros could be on track to launch its second product in the not-too-distant future.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Omeros Stock Quote
$2.14 (8.08%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.